Pharmacy Times The study by Patel et al demonstrates that choosing to use an antibiotic that does not inhibit CYP3A4 (eg, azithromycin) is a simple way to avoid the potential interaction with statins that are CYP3A4 substrates. Other antimicrobial agents that inhibit ...
InSerbia News However, she said, at the same time, new medications have been put on the list, and those are for acute myocardial infarction, cerebral infarction, hyperlipidemia ( rosuvastatin ), infections (cefpodoksim). As she said, various therapeutic options have ...
StreetInsider.com (subscription) Amarin Corporation plc (Nasdaq: AMRN) announced the results from a Phase 1 clinical trial that compared bioavailability of components fr...
Pharmacy Times Spending on mental health agents declined by $6.2 billion, as top agents Zyprexa (olanzapine), Seroquel ( quetiapine ), Geodon (ziprasidone HCl), and Lexapro (escitalopram) lost patent protection. Antihypertensives were highest in prescription volume, ...
SBWire (press release) The company will launch omeprazole, which is indicated for gastroesophageal reflux; antihypertensive therapeutic losartan; antidepressant escitalopram; immunosuppressive mycophenolate mofetil; rosuvastatin , which reduces cholesterol levels in the blood ...
The Pharma Letter ... AstraZeneca's blockbuster drug Crestor ( rosuvastatin calcium) for those mixed dyslipidemia patients at high risk of a cardiovascular event. AstraZeneca intends to pursue a large-scale cardiovascular outcomes trial for Epanova in combination with ... and more »
NASDAQ ... also in the news recently when it announced encouraging results from a phase I trial on its cardiovascular candidate, AMR-102, a fixed-dose combination of the company's only marketed product, Vascepa and AstraZeneca 's ( AZN ) Crestor ( rosuvastatin ). and more »
PMLiVE ... advantage of the drug's potential, and has previously said it plans to file supplemental marketing applications "as soon as possible" for Epanova in mixed dyslipidaemia and as a fixed-dose combination with its $6bn-plus statin drug Crestor ... and more »
